secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-07-08T23:59:59+00:00
Accession:  0001125345-22-000080
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics closes Phase 2 enoblituzumab study after 7 hemorrhagic fatalities in head and neck cancer
--------------------------------------------------------------------------------

- Phase 2 study CP-MGA271-06 closed due to 7 fatal hemorrhagic events among 62 SCCHN patients.
- 6 of 7 deaths assessed as unrelated to study treatment; 1 possibly related; incidence exceeded literature rate of 1–3.6%.
- Prior enoblituzumab studies in >340 patients had <1% fatal hemorrhage; nonclinical tox showed no coagulopathy.
- Company informed FDA and investigators; no new patients enrolled or treated as of July 7, 2022.
- Closure does not affect ongoing MGC018 ADC program; internal review and data analysis continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000080/0001125345-22-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000080/mgnx-20220708.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer